Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7077)
All Articles published online
|
Publishing Process of This Article
|
Feb 15, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ahrén B. Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World J Diabetes 2014; 5(1): 40-51 [PMID: 24567800 DOI: 10.4239/wjd.v5.i1.40] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v5/i1/40.htm |
| Number | Citing Articles |
| 1 |
Neil Skolnik, Debbie Hinnen, Yan Kiriakov, Melissa L. Magwire, John R. White. Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know. Clinical Diabetes 2018; 36(2): 174 doi: 10.2337/cd17-0048
|
| 2 |
Xiaoyan Yang, Peng Feng, Xiangjian Zhang, Dongfang Li, Ruifang Wang, Chenhui Ji, Guanglai Li, Christian Hölscher. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology 2019; 158: 107748 doi: 10.1016/j.neuropharm.2019.107748
|
| 3 |
Johan Farngren, Margaretha Persson, Bo Ahrén. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. Diabetes Care 2016; 39(2): 242 doi: 10.2337/dc15-1274
|
| 4 |
Neil Skolnik, Renell S. Dupree, Eric L. Johnson. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Current Medical Research and Opinion 2017; 33(12): 2187 doi: 10.1080/03007995.2017.1359518
|
| 5 |
Gerhard H. Scholz, Holger Fleischmann. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Therapeutic Advances in Endocrinology and Metabolism 2014; 5(5): 95 doi: 10.1177/2042018814556099
|
| 6 |
Tina Vilsbøll, Jiten Vora, Henrik Jarlov, Kajsa Kvist, Lawrence Blonde. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clinical Drug Investigation 2016; 36(4): 293 doi: 10.1007/s40261-016-0376-0
|
| 7 |
Bo Ahrén. Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition. Journal of Diabetes Investigation 2021; 12(7): 1128 doi: 10.1111/jdi.13564
|
| 8 |
Paula L. McClean, Christian Hölscher. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 2014; 86: 241 doi: 10.1016/j.neuropharm.2014.07.015
|
| 9 |
Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. 2015; : 3 doi: 10.1007/978-1-4471-4920-0_1
|
| 10 |
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, Flávio Reis. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?. Journal of Diabetes Research 2015; 2015: 1 doi: 10.1155/2015/806979
|
| 11 |
Sarah L. Greig, Lesley J. Scott. Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes. Drugs 2015; 75(13): 1523 doi: 10.1007/s40265-015-0448-0
|
| 12 |
Mie Tonoike, Daisuke Chujo, Mitsuhiko Noda. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes. Endocrinology, Diabetes & Metabolism 2019; 2(1) doi: 10.1002/edm2.43
|
| 13 |
Jennifer D. Goldman-Levine. Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. Annals of Pharmacotherapy 2015; 49(6): 688 doi: 10.1177/1060028015572653
|
| 14 |
Takahisa Hirose, Manabu Suzuki, Isao Tsumiyama. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study. Diabetes Therapy 2015; 6(4): 559 doi: 10.1007/s13300-015-0147-6
|
| 15 |
Katsuya Shibuki, Shuji Shimada, Takao Aoyama. Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2022; 16(4): 102474 doi: 10.1016/j.dsx.2022.102474
|
| 16 |
Shigeo Fuji, Sung-Won Kim, Shigemi Kamiya, Takahiko Nakane, Kenji Matsumoto, Yasushi Onishi, Kimikazu Yakushijin, Etsuko Yamazaki, Masayuki Hino, Saiko Kurosawa, Ken-ichi Yoshimura, Takahiro Fukuda. A multi-center prospective study randomizing the use of fat emulsion in intensive glucose control after allogeneic hematopoietic stem cell transplantation using a myeloablative conditioning regimen. Clinical Nutrition 2018; 37(5): 1534 doi: 10.1016/j.clnu.2017.08.022
|
| 17 |
Bo Ahrén. Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?. Diabetologia 2015; 58(8): 1740 doi: 10.1007/s00125-015-3557-0
|
| 18 |
Richard Simpson, Allen King. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?. Expert Review of Clinical Pharmacology 2015; 8(2): 179 doi: 10.1586/17512433.2015.1017562
|
| 19 |
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Ángel Martínez-González, Jordi Salas-Salvadó, Dolores Corella, Albert Goday, J. Alfredo Martínez, Ángel M. Alonso-Gómez, Olga Fernández-Barceló, Jesús Vioque, Dora Romaguera, José Lopez-Miranda, Ramón Estruch, Francisco J. Tinahones, José Lapetra, Lluís Serra-Majem, Blanca Riquelme-Gallego, Vicente Martín-Sánchez, Xavier Pintó, Miguel Delgado-Rodriguez, Pilar Matía, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefanía Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Ángel Muñoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Muñoz-Bravo, Salvador Miralles-Gisbert, Marian Martin, Antonio García-Ríos, Sara Castro-Barquero, José Carlos Fernández-García, José Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutiérrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Díez-Espino, Nancy Babio, Montse Fitó, Josep A. Tur. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomedicine & Pharmacotherapy 2023; 161: 114561 doi: 10.1016/j.biopha.2023.114561
|
| 20 |
Marcus Lind, Irl B. Hirsch, Jaakko Tuomilehto, Sofia Dahlqvist, Ole Torffvit, Nils-Gunnar Pehrsson. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Primary Care Diabetes 2015; 9(1): 15 doi: 10.1016/j.pcd.2014.07.010
|
| 21 |
Alhassane Diallo, Miguel Carlos-Bolumbu, Florence Galtier. Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. eClinicalMedicine 2022; 54: 101697 doi: 10.1016/j.eclinm.2022.101697
|
| 22 |
Andrea Tura, Johan Farngren, Anja Schweizer, James E. Foley, Giovanni Pacini, Bo Ahrén. Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. International Journal of Endocrinology 2015; 2015: 1 doi: 10.1155/2015/484231
|
| 23 |
Lisa J. Underland, Jeniece Trast Ilkowitz, Ranjitha Katikaneni, Amy Dowd, Rubina A. Heptulla. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes. Journal of Diabetes Science and Technology 2017; 11(3): 602 doi: 10.1177/1932296817699847
|
| 24 |
Jennifer Goldman, Jennifer M. Trujillo. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy 2017; 51(11): 990 doi: 10.1177/1060028017717281
|
| 25 |
Aline Haas de Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane de Bona Schraiber, Gislaine Tezza Rezin. Incretin-based therapies for obesity treatment. Metabolism 2015; 64(9): 967 doi: 10.1016/j.metabol.2015.05.012
|
| 26 |
Yasuo Terauchi, Yusuke Naito, Yukio Ikeda. Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2016; 10(1): 23 doi: 10.1016/j.dsx.2015.08.008
|
| 27 |
Martin Haluzík, Alena Adamíková, Milan Běhunčík, Marek Macko, Radka Štěpánová. Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic. Vnitřní lékařství 2018; 64(4): 357 doi: 10.36290/vnl.2018.053
|
| 28 |
Cristina Mega, Edite Teixeira-de-Lemos, Rosa Fernandes, Flávio Reis. Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes. Journal of Diabetes Research 2017; 2017: 1 doi: 10.1155/2017/5164292
|
| 29 |
S Fuji, A Rovó, K Ohashi, M Griffith, H Einsele, M Kapp, M Mohty, N S Majhail, B G Engelhardt, A Tichelli, B N Savani. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. Bone Marrow Transplantation 2016; 51(8): 1041 doi: 10.1038/bmt.2016.81
|
| 30 |
André J Scheen. A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 2015; 16(1): 43 doi: 10.1517/14656566.2015.978289
|
| 31 |
Lyudmila Alexandrovna Ruyatkina, Maxim Sorokin. Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance. Diabetes mellitus 2017; 20(2): 142 doi: 10.14341/7875
|
| 32 |
Guillermo Umpierrez. Approaches To Insulin Use. Endocrine Practice 2017; 23: 9 doi: 10.4158/1934-2403-23.s1.1
|
| 33 |
Bo Ahrén. Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development. Journal of Diabetes Investigation 2019; 10(2): 196 doi: 10.1111/jdi.12911
|
| 34 |
B. Ahrén. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabetes & Metabolism 2015; 41(6): 6S3 doi: 10.1016/S1262-3636(16)30002-7
|
| 35 |
Katsuya Shibuki, Shuji Shimada, Takao Aoyama, Daniela Foti. Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin. Journal of Diabetes Research 2020; 2020: 1 doi: 10.1155/2020/6321826
|
| 36 |
Yeong Gi Kim, Se Hee Min, Seokyung Hahn, Tae Jung Oh, Kyong Soo Park, Young Min Cho. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 2016; 116: 86 doi: 10.1016/j.diabres.2016.03.011
|
| 37 |
Johan Farngren, Bo Ahrén. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes. Metabolism 2019; 99: 25 doi: 10.1016/j.metabol.2019.06.016
|
| 38 |
Andrew J. Krentz, Christian Weyer, Marcus Hompesch. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 75 doi: 10.1007/978-3-030-11748-1_3
|
| 39 |
Arun K. Sharma, Punniyakoti V. Thanikachalam, Satyendra K. Rajput. Albiglutide: Is a better hope against diabetes mellitus?. Biomedicine & Pharmacotherapy 2016; 77: 120 doi: 10.1016/j.biopha.2015.12.015
|
| 40 |
R. G. Lentle, I. R. Sequeira, A. K. Hardacre, G. Reynolds. A method for assessing real time rates of dissolution and absorption of carbohydrate and other food matrices in human subjects. Food & Function 2016; 7(6): 2820 doi: 10.1039/C6FO00406G
|
| 41 |
Uchenna Anyanwagu, Jil Mamza, Richard Donnelly, Iskandar Idris. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. American Heart Journal 2018; 196: 18 doi: 10.1016/j.ahj.2017.10.003
|
| 42 |
John C. Clapham. Type 2 Diabetes. Methods in Molecular Biology 2020; 2076: 1 doi: 10.1007/978-1-4939-9882-1_1
|
| 43 |
Manel Mata‐Cases, Dídac Mauricio, Josep Franch‐Nadal. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. Journal of Diabetes 2017; 9(1): 34 doi: 10.1111/1753-0407.12373
|
| 44 |
Ohad Cohen, Sebastiano Filetti, Javier Castañeda, Marianna Maranghi, Mariela Glandt. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump. Diabetes Care 2016; 39(Supplement_2): S180 doi: 10.2337/dcS15-3029
|